• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Evaluation and significance of study endpoints--implications for evidence-based decisions in healthcare].

作者信息

Matthias Katja

机构信息

Gemeinsamer Bundesausschuss, Abteilung Fachberatung Medizin, Berlin.

出版信息

Z Evid Fortbild Qual Gesundhwes. 2010;104(3):272-6; discussion 277. doi: 10.1016/j.zefq.2010.03.008.

DOI:10.1016/j.zefq.2010.03.008
PMID:20608258
Abstract

The Federal Joint Committee (G-BA) is the most important decision-making body within the self-governing German healthcare system. The G-BA assessment of medical treatments and procedures follows a standardised procedure that rests on evidence-based medicine. As a rule, randomised controlled trials with patient-relevant endpoints (in particular mortality, morbidity, quality of life) are required for benefit assessments. Under certain conditions adequate studies with valid surrogate endpoints or composite endpoints may be taken into account in exceptional cases.

摘要

相似文献

1
[Evaluation and significance of study endpoints--implications for evidence-based decisions in healthcare].
Z Evid Fortbild Qual Gesundhwes. 2010;104(3):272-6; discussion 277. doi: 10.1016/j.zefq.2010.03.008.
2
[Decisions of the Federal Joint Committee for rejecting work with "weak" or failing evidence].[联邦联合委员会关于拒绝采用“薄弱”或无效证据开展工作的决定]
Z Evid Fortbild Qual Gesundhwes. 2010;104(4):323-9. doi: 10.1016/j.zefq.2009.12.029.
3
[Integrative assessment of evidence in healthcare: the GRADE system].[医疗保健中的证据综合评估:GRADE 系统]
Z Evid Fortbild Qual Gesundhwes. 2009;103(5):261-8. doi: 10.1016/j.zefq.2009.05.007.
4
[Decision of the Federal Joint Committee on screening for chorionicity - benefit assessment in the absence of screening studies].
Gesundheitswesen. 2013 Jan;75(1):13-21. doi: 10.1055/s-0032-1311615. Epub 2012 Jul 30.
5
To 'First, Do No Harm,' You Must Start With Good Evidence.要践行“首先,不伤害”的原则,你必须从可靠的证据开始。
Manag Care. 2016 Oct;25(10):30-33.
6
[Procedures and methods of benefit assessments for medicines in Germany].[德国药品效益评估的程序和方法]
Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25.
7
[Benefits and benefits assessment: the principles of evidence-based medicine and health technology assessment as a decisional basis for the federal joint committee].
Z Arztl Fortbild Qualitatssich. 2007;101(7):455-62. doi: 10.1016/j.zgesun.2007.08.004.
8
Procedures and methods of benefit assessments for medicines in Germany.德国药品效益评估的程序和方法。
Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.
9
Ten clinician-driven strategies for maximising value of Australian health care.优化澳大利亚医疗保健价值的十大临床主导策略。
Aust Health Rev. 2014 May;38(2):125-33. doi: 10.1071/AH13248.
10
[Health-related quality of life: a pivotal endpoint in benefit assessment of medical procedures].[健康相关生活质量:医疗程序获益评估中的关键终点]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Mar;58(3):283-90. doi: 10.1007/s00103-014-2107-0.